Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugs: A retrospective study

In view of the forthcoming long-acting antiretrovirals, measures should be taken to prevent the selection of HIV drug resistance mutations. All subjects who had been switched to boosted protease inhibitors plus maraviroc (bPIs/MVC) with baseline HIV-1 RNA >50 copies/mL between June, 2014, and Apr...

Descripción completa

Detalles Bibliográficos
Autores principales: Capetti, Amedeo Ferdinando, Micale, Mariangela, Carenzi, Laura, Niero, Fosca, Landonio, Simona, Vimercati, Stefania, Dedivitiis, Gianfranco, Rizzardini, Giuliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
4850
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319489/
https://www.ncbi.nlm.nih.gov/pubmed/28207500
http://dx.doi.org/10.1097/MD.0000000000005728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319489/
https://www.ncbi.nlm.nih.gov/pubmed/28207500
http://dx.doi.org/10.1097/MD.0000000000005728

Ejemplares similares